Fluconazole

• 

  Subject Areas on Research

  • A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis. 
  • A tetraploid intermediate precedes aneuploid formation in yeasts exposed to fluconazole. 
  • AIDS‐associated Cryptococcus neoformans and Penicillium marneffei coinfection: a therapeutic dilemma in resource‐limited settings. 
  • AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. 
  • Alopecia associated with fluconazole therapy. 
  • An observational study on the epidemiological and mycological profile of Candidemia in ICU patients. 
  • Antifungal Extraction by the Extracorporeal Membrane Oxygenation Circuit. 
  • Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis. 
  • Antifungal resistance: the clinical front. 
  • Antifungal therapy and outcomes in infants with invasive Candida infections. 
  • Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis. 
  • Breakthrough invasive fungal infections: Who is at risk? 
  • Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis. 
  • Calcineurin governs thermotolerance and virulence of Cryptococcus gattii. 
  • Calcineurin is essential for survival during membrane stress in Candida albicans. 
  • Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy. 
  • Candida albicans reprioritizes metal handling during fluconazole stress. 
  • Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. 
  • Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. 
  • Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation. 
  • Caspofungin versus amphotericin B for invasive candidiasis. 
  • Clinical characteristics and response to prophylactic fluconazole of preterm VLBW neonates with baseline and acquired fungal colonisation in NICU: data from a multicentre RCT. 
  • Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study. 
  • Clonal and spontaneous origins of fluconazole resistance in Candida albicans. 
  • Colony size can be used to determine the MIC of fluconazole for pathogenic yeasts. 
  • Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. 
  • Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. 
  • Congenital candidiasis: an uncommon skin eruption presenting at birth. 
  • Copper Availability Influences the Transcriptomic Response of Candida albicans to Fluconazole Stress. 
  • Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. 
  • Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. 
  • Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. 
  • Could risk assessment for non-albicans Candida improve empiric treatment for invasive candidiasis? 
  • Cryptococcal meningitis in patients with glioma: a report of two cases. 
  • Cryptococcal meningoencephalitis: time for action. 
  • Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. 
  • Cryptococcus neoformans methionine synthase: expression analysis and requirement for virulence. 
  • Cryptococcus neoformans phosphoinositide-dependent kinase 1 (PDK1) ortholog is required for stress tolerance and survival in murine phagocytes. 
  • Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. 
  • Cutaneous cryptococcosis in solid organ transplant recipients. 
  • Deletion of Cryptococcus neoformans AIF ortholog promotes chromosome aneuploidy and fluconazole-resistance in a metacaspase-independent manner. 
  • Dosing in neonates: special considerations in physiology and trial design. 
  • Dosing of Antimicrobials in the Neonatal Intensive Care Unit: Does Clinical Practice Reflect Pharmacokinetics-based Recommendations? 
  • Dynamic and heterogeneous mutations to fluconazole resistance in Cryptococcus neoformans. 
  • Editorial commentary: Fluconazole therapeutic drug monitoring in children with cancer: not today. 
  • Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants. 
  • Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. 
  • Elucidating the Candida albicans calcineurin signaling cascade controlling stress response and virulence. 
  • Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. 
  • External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models. 
  • First, do no harm. 
  • Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. 
  • Fluconazole Prophylaxis for the Prevention of Candidiasis in Premature Infants: A Meta-analysis Using Patient-level Data. 
  • Fluconazole analogues with metal-binding motifs impact metal-dependent processes and demonstrate antifungal activity in Candida albicans. 
  • Fluconazole and Candida krusei fungemia. 
  • Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. 
  • Fluconazole loading dose pharmacokinetics and safety in infants. 
  • Fluconazole pharmacokinetics and safety in premature infants. 
  • Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation. 
  • Fluconazole prophylaxis for prevention of invasive candidiasis in infants. 
  • Fluconazole therapy for experimental cryptococcosis and candidiasis in the rabbit. 
  • Genotypic diversity and clinical outcome of cryptococcosis in renal transplant recipients in Brazil. 
  • Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. 
  • Hepatic candidiasis: persistent pyrexia in a patient with acute myeloid leukaemia after recovery from consolidation therapy-induced neutropenia. 
  • Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. 
  • Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients. 
  • In Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates. 
  • In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. 
  • In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. 
  • In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. 
  • In-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida spp. 
  • Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers. 
  • Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. 
  • Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. 
  • Management of injuries caused by Cryptococcus neoformans--contaminated needles. 
  • Neonatal candidiasis: prophylaxis and treatment. 
  • Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. 
  • Old and new: appropriate dosing for neonatal antifungal drugs in the nursery. 
  • Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. 
  • Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. 
  • Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. 
  • Persistence of the same Candida albicans strain despite fluconazole therapy. Documentation by pulsed-field gel electrophoresis. 
  • Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. 
  • Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. 
  • Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. 
  • Pharmacotherapy of disseminated histoplasmosis in patients with AIDS. 
  • Phenotypic and genotypic evaluation of fluconazole resistance in vaginal Candida strains isolated from HIV-infected women from Brazil. 
  • Physiologically Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support: Fluconazole in Children on ECMO. 
  • Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants. 
  • Physiologically-Based Pharmacokinetic Modeling of Fluconazole Using Plasma and Cerebrospinal Fluid Samples From Preterm and Term Infants. 
  • Population Pharmacokinetics of Fluconazole in Premature Infants with Birth Weights Less than 750 Grams. 
  • Population pharmacokinetics of fluconazole in young infants. 
  • Population pharmacokinetics of sildenafil in extremely premature infants. 
  • Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. 
  • Predictors and outcomes of Candida bloodstream infection: eight-year surveillance, western Saudi Arabia. 
  • Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. 
  • Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. 
  • Reduced Visual Acuity Following Kidney Stone Extraction. 
  • Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. 
  • Structure-Guided Discovery of Potent Antifungals that Prevent Ras Signaling by Inhibiting Protein Farnesyltransferase. 
  • Successful treatment of Trichosporon mucoides infection with fluconazole in a heart and kidney transplant recipient. 
  • Surgical infection prophylaxis prior to left ventricular assist device implantation: A survey of clinical practice. 
  • Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. 
  • Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. 
  • Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model. 
  • The calcineurin target, Crz1, functions in azole tolerance but is not required for virulence of Candida albicans. 
  • The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis. 
  • Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304. 
  • Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. 
  • Trehalose pathway as an antifungal target. 
  • Unisexual and heterosexual meiotic reproduction generate aneuploidy and phenotypic diversity de novo in the yeast Cryptococcus neoformans. 
  • Use of fluconazole in a patient with documented malabsorption of ketoconazole. 
• 

  Keywords of People

  • Cohen-Wolkowiez, Michael, Professor of Pediatrics, Pediatrics, Infectious Diseases